Literature DB >> 16847959

Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.

Juan A Quiroga1, Silvia Llorente, Inmaculada Castillo, Elena Rodríguez-Iñigo, Juan Manuel López-Alcorocho, Margarita Pardo, Vicente Carreño.   

Abstract

Hepatitis C virus (HCV) RNA persistence in the liver has been described even after apparent resolution of HCV infection. Because T-cell reactivity plays a role in recovery from HCV infection, virus-specific T-cell responses were investigated in apparently recovered individuals in whom hepatic HCV RNA persistence was documented: 15 sustained virological responders to interferon (IFN)-treatment and 9 asymptomatic aviremic anti-HCV carriers. HCV-specific CD4(+) T-cell proliferative responses were detected significantly more often in apparently recovered individuals (sustained virological responders: 60%; asymptomatic anti-HCV carriers: 66%) compared with 50 chronic hepatitis C patients (28%; P < 0.05). However, T-cell frequencies and numbers tended to decline over time and the number of HCV proteins targeted by CD4(+) T-cell proliferative responses was limited. Interestingly, liver viral load correlated inversely with virus-specific immune responses. Thus, CD4(+) T-cell responders showed significantly lower hepatic HCV RNA levels (P < 0.05). HCV-specific IFN-gamma-secreting CD4(+) T-cells were not detected in all the apparently recovered patients although they were found significantly more often compared with chronic hepatitis C patients (P < 0.05). Also, HCV NS3-specific CD8(+) T-cells were detected in 11 HLA-A2-positive apparently recovered individuals (8 sustained virological responders and 3 asymptomatic anti-HCV carriers); T-cell frequencies tended to be greater in those patients who had lower hepatic viral levels. In conclusion, HCV-specific T-cells are detectable in apparently recovered individuals in whom HCV RNA can persist in the liver indicating that HCV replication may be prolonged in the face of an insufficient or inadequate virus-specific CD4(+) and CD8(+) T-cell response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847959     DOI: 10.1002/jmv.20680

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

2.  Occult persistence and lymphotropism of hepatitis C virus infection.

Authors:  Tram-Nq Pham; Tomasz-I Michalak
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

3.  The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use.

Authors:  F-C Tseng; B R Edlin; M Zhang; A Kral; M P Busch; B A Ortiz-Conde; T M Welzel; T R O'Brien
Journal:  J Viral Hepat       Date:  2008-05-27       Impact factor: 3.728

4.  The altered expression of α1 and β3 subunits of the gamma-aminobutyric acid A receptor is related to the hepatitis C virus infection.

Authors:  M Sidorkiewicz; M Brocka; M Bronis; M Grek; B Jozwiak; A Piekarska; J Bartkowiak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-13       Impact factor: 3.267

5.  Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.

Authors:  Jeong Heo
Journal:  Korean J Hepatol       Date:  2011-09

6.  Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.

Authors:  Isabelle Moreau; John Levis; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  Virol J       Date:  2008-07-09       Impact factor: 4.099

Review 7.  A New Twist to a Chronic HCV Infection: Occult Hepatitis C.

Authors:  Bashar M Attar; David Van Thiel
Journal:  Gastroenterol Res Pract       Date:  2015-06-24       Impact factor: 2.260

8.  Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.

Authors:  Annie Y Chen; Marija Zeremski; Ranjit Chauhan; Ira M Jacobson; Andrew H Talal; Tomasz I Michalak
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.